Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Lantern Pharma Inc. (LTRN)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
3 days ago | Benzinga
4 days ago | PRNewsWire
2 weeks ago | PRNewsWire
2 weeks ago | PRNewsWire
2 weeks ago | GlobeNewsWire
3 weeks ago | PRNewsWire
3 weeks ago | Pulse2
3 weeks ago | Benzinga
3 weeks ago | PRNewsWire
2 months ago | Benzinga
About:
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.